trifluoperazine and Multiple Myeloma studies

trifluoperazine and Multiple Myeloma

Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.

Research Excerpts

Excerpt	Relevance	Reference
"Trifluoperazine (TFP) is a clinical drug for acute and chronic psychosis therapy."	5.72	Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK/NUPR1. ( Chen, J; Chen, X; Chen, Y; Jing, Z; Li, A; Yu, W, 2022)
"Trifluoperazine (TFP) is a clinical drug for acute and chronic psychosis therapy."	1.72	Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK/NUPR1. ( Chen, J; Chen, X; Chen, Y; Jing, Z; Li, A; Yu, W, 2022)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (66.67)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

1 (33.33)

18.2507

2000's

0 (0.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

2 (66.67)

2.80

Authors

Authors	Studies
Jing, Z	2
Yu, W	1
Li, A	2
Chen, X	2
Chen, Y	1
Chen, J	2
Lehnert, M	1
Emerson, S	1
Dalton, WS	1
de Giuli, R	1
Salmon, SE	1

Studies

Jing, Z

Yu, W

Li, A

Chen, X

Chen, Y

Chen, J

Lehnert, M

Emerson, S

Dalton, WS

de Giuli, R

Salmon, SE

Other Studies

3 other studies available for trifluoperazine and Multiple Myeloma

Article	Year
Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK/NUPR1. The Tohoku journal of experimental medicine, 2022, Jul-22, Volume: 257, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Bortezomib; Cell Lin	2022
Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma. FEBS open bio, 2020, Volume: 10, Issue:10 Topics: Apoptosis; Autophagy; Basic Helix-Loop-Helix Transcription Factors; Cell Cycle; Cell Line, Tumor; Ce	2020
In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. Journal of the National Cancer Institute. Monographs, 1993, Issue:15 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cyclosporine; Drug Resist	1993

Article

Year

Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK/NUPR1.

The Tohoku journal of experimental medicine, 2022, Jul-22, Volume: 257, Issue:4

Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Bortezomib; Cell Lin

2022

Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma.

FEBS open bio, 2020, Volume: 10, Issue:10

Topics: Apoptosis; Autophagy; Basic Helix-Loop-Helix Transcription Factors; Cell Cycle; Cell Line, Tumor; Ce

2020

In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance.

Journal of the National Cancer Institute. Monographs, 1993, Issue:15

Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cyclosporine; Drug Resist

1993